Loss of FCN3 links cirrhotic matrix stiffness to YAP activation in HCC
- 1Department of Anesthesiology, Renji Hospital, Shanghai Jiao Tong University School of Medicine; Key Laboratory of Anesthesiology (Shanghai Jiao Tong University), Ministry of Education
- 2State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Abstract
Background Cirrhosis-associated matrix stiffness is a major biophysical driver of hepatocellular carcinoma (HCC). How fibrosis-induced stiffness activates oncogenic YAP signaling remains unclear. We investigated the role of ficolin-3 (FCN3) in stiffness-associated regulation of the O-GlcNAc transferase (OGT)–YAP axis in HCC. Methods Public transcriptomic datasets comparing cirrhotic and normal liver tissues (GSE114564), as well as HCC tissues from patients with and without cirrhosis (GSE14520), were analyzed. FCN3 protein expression was evaluated in 67 paired HCC and adjacent non-tumorous tissues, and a subset of 20 matched cases was further analyzed by quantitative reverse-transcription PCR and atomic force microscopy. Controlled-stiffness substrates, FCN3 gain- and loss-of-function models, and murine H22 allograft and human HepG2 xenograft models were used for functional validation. Mechanistic studies included RNA sequencing, cycloheximide chase assays, subcellular fractionation, co-immunoprecipitation, structural prediction, YAP-S127A rescue, Thiamet-G treatment, and YAP knockdown. Results FCN3 was downregulated in cirrhotic liver and HCC with cirrhosis. In clinical samples, tumor stiffness inversely correlated with FCN3 expression. FCN3 overexpression curtailed proliferation, clonogenicity, migration, and invasion in vitro and suppressed tumor growth in vivo. Transcriptomics revealed YAP pathway inhibition without changes in upstream kinases. FCN3 did not alter YAP mRNA but reduced YAP protein, increased p-YAP(S127), limited nuclear YAP, and shortened YAP half-life. Co-IP showed FCN3 binds OGT and disrupts OGT–YAP association, decreasing YAP O-GlcNAcylation. YAP knockdown partially attenuated FCN3’s anti-tumor effects. Conclusions These findings support a stiffness-associated FCN3–OGT–YAP regulatory model in HCC, in which FCN3 expression is associated with reduced OGT–YAP interaction, decreased YAP O-GlcNAcylation, and restricted YAP nuclear activity. Further studies are required to establish direct molecular competition and its independence from canonical Hippo–LATS signaling.
Related
- Paired-surface spatial mechanomics links tissue stiffness maps to spatial transcriptomics
- Dynamic hybrid-hydrogel lung models decouple matrix composition, stiffness, and fibroblast conditioning to define distinct drivers of fibrotic progression
- ITGB1 Contributes to Matrix Stiffness–Induced Lipid Raft Organization and Promotes Hepatocellular Carcinoma Cell Migration
- A glucosylcholesterol-cytoskeleton axis links GBA2 loss-of-function to synaptic and mitochondrial pathology in Hereditary Spastic Paraplegia
- Extracellular matrix stiffness determines the phenotypic behavior of dedifferentiated melanoma cells through a DDR1/2-dependent YAP mechanotransduction pathway
BibTeX
@article{luo2026loss,
title = {{Loss of FCN3 links cirrhotic matrix stiffness to YAP activation in HCC}},
author = {Jia-Mei Luo and Wei Xuan and Guojun Qian and Yiying Tao and Xiaoqiang Wang and Yuqing Chen and Jialin Wu and Zhi-Gang Zhang and Jie Tian},
journal = {Journal of Translational Medicine},
year = {2026},
month = aug,
doi = {10.1186/s12967-026-08795-7},
url = {https://doi.org/10.1186/s12967-026-08795-7},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Loss of FCN3 links cirrhotic matrix stiffness to YAP activation in HCC
AU - Jia-Mei Luo
AU - Wei Xuan
AU - Guojun Qian
AU - Yiying Tao
AU - Xiaoqiang Wang
AU - Yuqing Chen
AU - Jialin Wu
AU - Zhi-Gang Zhang
AU - Jie Tian
PY - 2026
DA - 2026/08/01
JO - Journal of Translational Medicine
DO - 10.1186/s12967-026-08795-7
UR - https://doi.org/10.1186/s12967-026-08795-7
AB - Background Cirrhosis-associated matrix stiffness is a major biophysical driver of hepatocellular carcinoma (HCC). How fibrosis-induced stiffness activates oncogenic YAP signaling remains unclear. We investigated the role of ficolin-3 (FCN3) in stiffness-associated regulation of the O-GlcNAc transferase (OGT)–YAP axis in HCC. Methods Public transcriptomic datasets comparing cirrhotic and normal liver tissues (GSE114564), as well as HCC tissues from patients with and without cirrhosis (GSE14520), were analyzed. FCN3 protein expression was evaluated in 67 paired HCC and adjacent non-tumorous tissues, and a subset of 20 matched cases was further analyzed by quantitative reverse-transcription PCR and atomic force microscopy. Controlled-stiffness substrates, FCN3 gain- and loss-of-function models, and murine H22 allograft and human HepG2 xenograft models were used for functional validation. Mechanistic studies included RNA sequencing, cycloheximide chase assays, subcellular fractionation, co-immunoprecipitation, structural prediction, YAP-S127A rescue, Thiamet-G treatment, and YAP knockdown. Results FCN3 was downregulated in cirrhotic liver and HCC with cirrhosis. In clinical samples, tumor stiffness inversely correlated with FCN3 expression. FCN3 overexpression curtailed proliferation, clonogenicity, migration, and invasion in vitro and suppressed tumor growth in vivo. Transcriptomics revealed YAP pathway inhibition without changes in upstream kinases. FCN3 did not alter YAP mRNA but reduced YAP protein, increased p-YAP(S127), limited nuclear YAP, and shortened YAP half-life. Co-IP showed FCN3 binds OGT and disrupts OGT–YAP association, decreasing YAP O-GlcNAcylation. YAP knockdown partially attenuated FCN3’s anti-tumor effects. Conclusions These findings support a stiffness-associated FCN3–OGT–YAP regulatory model in HCC, in which FCN3 expression is associated with reduced OGT–YAP interaction, decreased YAP O-GlcNAcylation, and restricted YAP nuclear activity. Further studies are required to establish direct molecular competition and its independence from canonical Hippo–LATS signaling.
SN - 1479-5876
ER -